PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline coul...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
PAGEPress Publications
2012-06-01
|
| Serija: | Mediterranean Journal of Hematology and Infectious Diseases |
| Teme: | |
| Online pristup: | http://www.mjhid.org/index.php/mjhid/article/view/371 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|